teclistamab

High Alert

Relapsed or refractory multiple myeloma in patients who have previously received ≥4 lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Contraindicated in:

OB: Pregnancy;
Lactation: Lactation.

Use Cautiously in:

Rep: Women of reproductive potential;
Pedi: Safety and effectiveness not established in children.

CV: arrhythmia, edema, hypertension, hypotension

F and E: hypocalcemia, hyponatremia, hypophosphatemia

GI: constipation, diarrhea, hepatotoxicity, hypoalbuminemia, nausea, vomiting

GU: acute kidney injury

Hemat: hemorrhage, neutropenia, anemia, leukopenia, lymphopenia, thrombocytopenia

Local: injection site reactions

Metab: ↓appetite

MS: pain

Neuro: encephalopathy, fatigue, headache, motor dysfunction, neuropathy, Guillain-Barré syndrome, IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME (ICANS), PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY, SEIZURE

Resp: cough, hypoxia

Misc: cytokine release syndrome (CRS), hypogammaglobulinemia, infection, chills, fever, hypersensitivity reactions

Drug-drug:

May suppress activity of CYP450 drug-metabolizing enzymes (especially within 7 days after first dose and during/after onset of cytokine release syndrome); careful monitoring of CYP450 substrates is recommended.

Solution for SUBQ injection: 10 mg/mL; 90 mg/mL

SC (Adults ): Day 1 (step-up dose 1): 0.06 mg/kg as single dose; Day 4 (step-up dose 2): 0.3 mg/kg as single dose; Day 7 (1st treatment dose): 1.5 mg/kg as single dose; Weekly dosing schedule: 1.5 mg/kg administered 1 wk after 1st treatment dose and then once weekly thereafter until disease progression or unacceptable toxicity. If patient achieves and maintains at least a complete response for ≥6 mo, may change to 1.5 mg/kg every 2 wk until disease progression or unacceptable toxicity.

Tecvayli

Acts as a T-cell engager, binding to the CD3 receptor expressed on the surface of T-cells and B-cell maturation antigen expressed on the surface of multiple myeloma cells, resulting in facilitated lysis of malignant cells.

Therapeutic effects:

Slowed progression of multiple myeloma.

Therapeutic Classification: antineoplastics

Pharmacologic Classification: T-cell engagers

Absorption: 72% absorbed following SUBQ administration.

Distribution: Not extensively distributed to tissues.

Metabolism/Excretion: Unknown.

Half-Life: Unknown.

(plasma concentrations)

ROUTE	ONSET	PEAK	DURATION
SUBQ	unknown	139 hr (after 1st dose); 72 hr (after 13th dose)	unknown

Explain purpose and side effects of medication to patient. Advise patient to read Patient Information before starting therapy.
Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult health care professional before taking other medications.
Advise patient to notify health care professional promptly if signs and symptoms of CRS (fever [≥100.4°F], feeling anxious, difficulty breathing, confusion or restlessness, chills, headache, dizziness, light-headedness, ↑ liver enzymes, fast heartbeat), neurologic problems (headache, confusion, changes in handwriting, jerking movements, trouble speaking, problems walking, rigid muscles, muscle spasms, muscle weakness in body or face, feeling restless, tremor, hearing loss, numbness, double vision, burning, throbbing, stabbing pain, tingling), liver problems (tiredness, pain in right upper abdomen, loss of appetite, dark urine, yellowing of skin or white part of eyes), or upper respiratory infections occur.
May cause dizziness. Caution patient to avoid driving and other activities requiring alertness until response to teclistamab is known.
Inform patients that hospitalization may be required for 48 hr after dose administration.
Rep: May cause fetal harm. Advise females of reproductive potential to use effective contraception and avoid breastfeeding during and for 5 mo after last dose of therapy. Assess immunoglobulin levels in newborns of mothers treated with teclistamab.
Instruct patient to carry the Tecvayli Patient Wallet Card with them at all times and show it to all their health care professionals. The wallet card lists signs and symptoms of CRS and neurologic problems.

tek-LIST-uh-mab

section name header

Indications ⬇

Contraind./Precautions ⬆ ⬇

Adv. Reactions/Side Effects ⬆ ⬇

Interactions ⬆ ⬇

Availability ⬆ ⬇

Route/Dosage ⬆ ⬇

US Brand Names ⬆ ⬇

Action ⬆ ⬇

Classifications ⬆ ⬇

Pharmacokinetics ⬆ ⬇

Time/Action Profile ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Pronunciation ⬆